Abbott Laboratories Divestiture
Abbott Laboratories announced its intention to separate its global Nutrition business into an independent, publicly traded company via a tax-free distribution to shareholders. The new entity will be a global leader in healthy nutrition with approximately $8.5 billion in annual sales and a portfolio including brands like Similac, Ensure, and PediaSure. The separation is expected to be completed by the end of 2027.
“As we continue to shape Abbott for the future, this separation will benefit both companies, setting each one up for maximum success in its respective market. Our Nutrition business has a unique opportunity to capitalize on the growing demand for healthy nutrition, and it will be better positioned as an independent company to more effectively direct its strategic resources across its priorities.”
Robert B. Ford, chairman and chief executive officer, Abbott